You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

January 15, 2021

Hemp Now Legally Permitted for Use in Cosmetics in Thailand

Following the recent delisting of almost all parts of the hemp plant from Thailand’s list of prohibited narcotics (see here for further details), the Ministry of Public Health has issued a notification allowing hemp to be used in cosmetics. Prior to this development, this use of hemp (whether from natural or synthetic sources) was not allowed, as it fell under the definition of narcotics under the Notification Re: Ingredients Not Allowed for Use in Cosmetics B.E. 2559 (2016).

Under the Ministerial Notification Re: Use of Hemp in Cosmetics B.E. 2564 (2021), which was published in the Government Gazette on January 11, 2021, domestic manufacturers are now allowed to produce cosmetics containing hemp seed oil or hemp seed extract, provided the cosmetics do not have a THC level exceeding 0.2% by weight.

To register such products with the Thai FDA, applicants must submit a certificate of analysis, safety data sheet, and label for the agency’s evaluation. The timeline for approval of the registration (notification) of a cosmetic containing hemp seed oil or hemp seed extract is three business days. The applicant (i.e., manufacturer or toll manufacturer) must declare the amount of hemp seed extract or hemp seed oil used in the cosmetic in their notification application. Cosmetics must not use a name for the product that evokes an association with hemp flowers or narcotics, and the name of the product must be within the scope of cosmetics. For example, names containing “inflorescence,” “flower,” “CBD,” “THC” or similar will not be allowed.

It should also be noted that Thailand does not yet allow the importation of cosmetics containing hemp seeds or hemp seed extract, and this regulation only applies to domestically produced hemp products—a business currently restricted to individuals or companies with Thai nationality.

For more details on this development, or on any aspect of hemp and cannabis regulations in Thailand, please contact Tilleke & Gibbins at [email protected].

RELATED INSIGHTS​ 

September 19, 2019
The August 2019 edition of Global Regulatory Press’ Journal of Medical Device Regulation  features a Vietnam overview authored by two of Tilleke & Gibbins’ regulatory affair specialists in the jurisdiction—Hien Thi Thu Vu, head of the regulatory affairs team in Vietnam, and Mai Thi Le, regulatory affairs consultant in Vietnam.
September 19, 2019
Dr. Atthachai Homhuan, manager of regulatory affairs at Tilleke & Gibbins, recently contributed the Thailand overview for the May 2019 edition of Global Regulatory Press’ Journal of Medical Device Regulation —an industry-specific journal that provides an insider’s perspective into the regulatory world surrounding medical devices in jurisdictions around the world.In the Thailand overview, Dr. Atthachai covers the following topics:
September 5, 2019
On Friday August 30, 2019, a Notification of the Thai Ministry of Public Health (“MOPH Notification”) was published in the Government Gazette. The MOPH Notification went into effect on August 31, 2019, one day after its publication.This MOPH Notification outlines another Thai Government initiative in connection with the free cannabis policy, this time carving out further aspects of marijuana and hemp use from the stringent regulations under the Narcotics Act.
September 4, 2019
The 2019 edition of Thomson Reuters’ Practical Law Life Sciences Global Guide  has been released, with its Pharmaceutical Intellectual Property and Competition Law in Cambodia chapter written by practitioners from Tilleke & Gibbins’ Phnom Penh office.The guide is a Q&A-style overview of the regulatory frameworks for the life sciences industries across jurisdictions worldwide. This chapter on pharmaceutical IP and competition law in Cambodia addresses the following issues in the country’s legal landscape for life sciences: